Targeting the blood vessels that feed tumours is not the silver bullet once hoped for, but refinements to the strategy may suggest further ways to treat the disease. Erika Check Hayden reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo
BMC Cancer Open Access 14 March 2017
-
Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis
BMC Cancer Open Access 15 October 2013
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Folkman, J. N. Engl. J. Med. 285, 1182–1186 (1971).
Pàez-Ribes, M. et al. Cancer Cell 15, 220–231 (2009).
Ebos, J. M. L. et al. Cancer Cell 15, 232–239 (2009).
Reynolds, A. R. et al. Nature Med. doi:10.1038/nm.1941 (2009).
Pennacchietti, S. et al. Cancer Cell 3, 347–361 (2003).
Additional information
See Editorial, page 679 .
Related links
Related links
Related links in Nature Research
Nature Reviews Cancer: When good drugs do bad things
Nature Reviews Cancer Focus on Targeting Angiogenesis
Related external links
US National Cancer Institute fact sheet on angiogenesis inhibitors
Rights and permissions
About this article
Cite this article
Hayden, E. Cutting off cancer's supply lines. Nature 458, 686–687 (2009). https://doi.org/10.1038/458686b
Published:
Issue Date:
DOI: https://doi.org/10.1038/458686b
This article is cited by
-
Evaluation of tumor microvasculature with 3D ultrasound localization microscopy based on 2D matrix array
European Radiology (2024)
-
Endothelial Dll4 overexpression reduces vascular response and inhibits tumor growth and metastasization in vivo
BMC Cancer (2017)
-
Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis
BMC Cancer (2013)
-
Fighting against cancer by integrative medicine
Chinese Journal of Integrative Medicine (2012)
-
A retroperitoneal NF1-independent malignant peripheral nerve sheath tumor with elevated serum CA125: case report and discussion
Journal of Neuro-Oncology (2012)